Fleming DT, McQuillan GM, Johnson RE.
et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med.1997;337:1105-1111.
Koutsky LA, Ashley RL, Holmes KK.
et al. The frequency of unrecognized type 2 herpes simplex virus infection
among women: implications for the control of genital herpes. Sex Transm Dis.1990;17:90-94.
Cunningham AL, Lee FK, Ho DW.
et al. Herpes simplex virus type 2 antibody in patients attending antenatal
or STD clinics. Med J Aust.1993;158:525-528.
Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus
infection in the world. Scand J Infect Dis Suppl.1990;69:19-36.
Siegel D, Golden E, Washington AE.
et al. Prevalence and correlates of herpes simplex infections: the population-based
AIDS in Multiethnic Neighborhoods Study. JAMA.1992;268:1702-1708.
Forsgren M. Genital herpes simplex virus infection and incidence of neonatal disease
in Sweden. Scand J Infect Dis Suppl.1990;69:37-41.
Brown ZA, Selke S, Zeh J.
et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med.1997;337:509-515.
Holmberg SD, Stewart JA, Gerber AR.
et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV
Wasserheit JN. Epidemiological synergy: interrelationships between human immunodeficiency
virus infection and other sexually transmitted diseases. Sex Transm Dis.1992;19:61-77.
Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions
in HIV-1–infected men. JAMA.1998;280:61-66.
Brown ZA, Vontver LA, Benedetti J.
et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med.1987;317:1246-1251.
Yeager AS, Arvin AM, Urbani LJ, Kemp III JA. Relationship of antibody to outcome in neonatal herpes simplex virus
infections. Infect Immun.1980;29:532-538.
Sullender WM, Miller JL, Yasukawa LL.
et al. Humoral and cell-mediated immunity in neonates with herpes simplex
virus infection. J Infect Dis.1987;155:28-37.
Schmidt OW, Fife KH, Corey L. Reinfection is an uncommon occurrence in patients with symptomatic
recurrent genital herpes. J Infect Dis.1984;149:645-646.
Lakeman AD, Nahmias AJ, Whitley RJ. Analysis of DNA from recurrent genital herpes simplex virus isolates
by restriction endonuclease digestion. Sex Transm Dis.1986;13:61-66.
Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections. Ann Intern Med.1983;98:958-972.
Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med.1992;116:197-202.
Bryson Y, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners
of persons with genital herpes. J Infect Dis.1993;167:942-946.
Burke RL. Contemporary approaches to vaccination against herpes simplex virus. Curr Top Microbiol Immunol.1992;179:137-158.
Dix RD, Pereira L, Baringer JR. Use of monoclonal antibody directed against herpes simplex virus glycoproteins
to protect mice against acute virus-induced neurological disease. Infect Immun.1981;34:192-199.
Balachandran N, Bacchetti S, Rawls WE. Protection against lethal challenge of BALB/c mice by passive transfer
of monoclonal antibodies to five glycoproteins of herpes simplex virus type
2. Infect Immun.1982;37:1132-1137.
Byars NE, Fraser-Smith EB, Pecyk RA.
et al. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex
virus in an efficacious adjuvant formulation elicits protection against vaginal
Wachsman M, Aurelian L, Smith CC, Lipinskas BR, Perkus ME, Paoletti E. Protection of guinea pigs from primary and recurrent herpes simplex
virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing
HSV glycoprotein D. J Infect Dis.1987;155:1188-1197.
Langenberg AG, Burke RL, Adair SF.
et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2. Ann Intern Med.1995;122:889-898.
Ashley R, Cent A, Maggs V, Nahmias A, Corey L. Inability of enzyme immunoassays to discriminate between infections
with herpes simplex virus types 1 and 2. Ann Intern Med.1991;115:520-526.
Safrin S, Arvin A, Mills J, Ashley R. Comparison of the Western immunoblot assay and a glycoprotein G enzyme
immunoassay for detection of serum antibodies to herpes simplex virus type
2 in patients with AIDS. J Clin Microbiol.1992;30:1312-1314.
Ashley R. Herpes simplex virus. In: Lenette E, ed. Diagnostic Procedures for Viral,
Rickettsial and Chlamydial Infections. 7th ed. Washington, DC: American
Public Health Association; 1995:375-395.
Dalessio J, Ashley R. Highly sensitive enhanced chemiluminescence immunodetection method
for herpes simplex virus type 2 Western immunoblot. J Clin Microbiol.1992;30:1005-1007.
Alexander D, DiNello R, George-Nascimento C, Polito A, Sharma S, Burke RL. Simultaneous use of derivatives of glycoproteins gB1, gG1, gG2 and gD as antigens for type-specific serologic assay
to diagnose prior infection with HSV-1 or HSV-2. Abstract presented at: Eurogin International Conference on Herpes
Viruses and Genital Pathology; Paris, France; October 24, 1996.
Mertz GJ, Ashley R, Burke RL.
et al. Double-blind, placebo-controlled trial of a herpes simplex virus type
2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis.1990;161:653-660.
Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance
for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics.1986;42:507-519.
Bernstein D, Lagakos S. Sample size and power determination of stratified clinical trials. J Stat Comp Sim.1978;8:65-73.
Fleiss JL. The Design and Analysis of Clinical Experiments. New York, NY: John Wiley & Sons; 1986.
Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York, NY: McGraw-Hill; 1971.
Cox DR. Regression models and life-tables. J R Stat Soc [B].1972;34:187-220.
Fleming TR, Harrington DP. Counting Processes and Survival Analysis. New York, NY: John Wiley & Sons; 1991.
Kleinbaum DG, Kapper LL, Muller KE. Applied Regression Analysis and Other Multivariable
Methods. Boston, Mass: PWS-Kent Publishing Co; 1988.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc.1958;53:457-481.
SAS Institute Inc. SAS User's Guide: Statistics, Version 6. 2nd ed. Cary, NC: SAS Institute; 1985.
Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent
women. J Clin Invest.1997;99:1092-1097.
Terhune SS, Coleman KT, Sekulovich R, Burke RL, Spear PG. Limited variability of glycoprotein gene sequences and neutralizing
targets in herpes simplex virus type 2 isolates and stability on passage in
cell culture. J Infect Dis.1998;178:8-15.
Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin AM. Low risk of herpes simplex virus infections in neonates exposed to
the virus at the time of vaginal delivery to mothers with recurrent genital
herpes simplex virus infections. N Engl J Med.1987;316:240-244.
Rooney JF, Felser JM, Ostrove JM, Straus SE. Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med.1986;314:1561-1564.
Mertz GJ, Schmidt O, Jourden JL.
et al. Frequency of acquisition of first-episode genital infection with herpes
simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis.1985;12:33-39.
Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes
infections. N Engl J Med.1995;333:770-775.